Based on this, we hypothesize that RC48, either alone or in combination with dabrafenib, a clinical stage BRAF inhibitor, may offer improved clinical benefits for patients with BRAF-mutant cutaneous melanoma. This evidence concerns the gene BRAF and cutaneous melanoma.